These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 15111259)

  • 1. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia.
    Rodríguez De Fonseca F; Gorriti MA; Bilbao A; Escuredo L; García-Segura LM; Piomelli D; Navarro M
    Neurotox Res; 2001 Jan; 3(1):23-35. PubMed ID: 15111259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Behavioral effects of cannabinoid agents in animals.
    Chaperon F; Thiébot MH
    Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids Stimulate the TRP Channel-Dependent Release of Both Serotonin and Dopamine to Modulate Behavior in
    Oakes M; Law WJ; Komuniecki R
    J Neurosci; 2019 May; 39(21):4142-4152. PubMed ID: 30886012
    [No Abstract]   [Full Text] [Related]  

  • 4. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors.
    Martín AB; Fernandez-Espejo E; Ferrer B; Gorriti MA; Bilbao A; Navarro M; Rodriguez de Fonseca F; Moratalla R
    Neuropsychopharmacology; 2008 Jun; 33(7):1667-79. PubMed ID: 17957223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoid modulation of the dopaminergic circuitry: implications for limbic and striatal output.
    Fitzgerald ML; Shobin E; Pickel VM
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jul; 38(1):21-9. PubMed ID: 22265889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cannabinoids on dopamine release in the corpus striatum and the nucleus accumbens in vitro.
    Szabo B; Müller T; Koch H
    J Neurochem; 1999 Sep; 73(3):1084-9. PubMed ID: 10461898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of cannabinoids on the brain.
    Ameri A
    Prog Neurobiol; 1999 Jul; 58(4):315-48. PubMed ID: 10368032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neurobiology and evolution of cannabinoid signalling.
    Elphick MR; Egertová M
    Philos Trans R Soc Lond B Biol Sci; 2001 Mar; 356(1407):381-408. PubMed ID: 11316486
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The therapeutic role of cannabinoid receptors and its agonists or antagonists in Parkinson's disease.
    Han QW; Yuan YH; Chen NH
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jan; 96():109745. PubMed ID: 31442553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease.
    Di Marzo V; Hill MP; Bisogno T; Crossman AR; Brotchie JM
    FASEB J; 2000 Jul; 14(10):1432-8. PubMed ID: 10877836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis and cannabinoids: pharmacology and therapeutic potential.
    Śmiarowska M; Białecka M; Machoy-Mokrzyńska A
    Neurol Neurochir Pol; 2022; 56(1):4-13. PubMed ID: 35133644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic deletion of dopamine D1 receptors increases the sensitivity to cannabinoid CB1 receptor antagonist-precipitated withdrawal when compared with wild-type littermates: studies in female mice repeatedly exposed to the Spice cannabinoid HU-210.
    Serrano A; Vadas E; Ferrer B; Bilbao A; Granado N; Suárez J; Pavon FJ; Moratalla R; Rodríguez de Fonseca F
    Psychopharmacology (Berl); 2021 Feb; 238(2):551-557. PubMed ID: 33410990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological actions of cannabinoids.
    Pertwee RG
    Handb Exp Pharmacol; 2005; (168):1-51. PubMed ID: 16596770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
    Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
    CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders.
    van der Stelt M; Di Marzo V
    Eur J Pharmacol; 2003 Nov; 480(1-3):133-50. PubMed ID: 14623357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of pre- and perinatal exposure to hashish extracts on the ontogeny of brain dopaminergic neurons.
    Rodríguez de Fonseca F; Cebeira M; Fernández-Ruiz JJ; Navarro M; Ramos JA
    Neuroscience; 1991; 43(2-3):713-23. PubMed ID: 1922791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the endogenous cannabinoid system in the regulation of motor activity.
    Rodríguez de Fonseca F; Del Arco I; Martín-Calderón JL; Gorriti MA; Navarro M
    Neurobiol Dis; 1998 Dec; 5(6 Pt B):483-501. PubMed ID: 9974180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cannabinoid-dopamine interactions in the physiology and physiopathology of the basal ganglia.
    García C; Palomo-Garo C; Gómez-Gálvez Y; Fernández-Ruiz J
    Br J Pharmacol; 2016 Jul; 173(13):2069-79. PubMed ID: 26059564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
    González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
    Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
    Pertwee RG
    Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.